A detailed history of Leavell Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Leavell Investment Management, Inc. holds 5,700 shares of CRSP stock, worth $272,916. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,700
Previous 12,650 54.94%
Holding current value
$272,916
Previous $683,000 60.91%
% of portfolio
0.01%
Previous 0.04%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$44.62 - $62.75 $310,109 - $436,112
-6,950 Reduced 54.94%
5,700 $267,000
Q2 2024

Jul 17, 2024

BUY
$51.17 - $68.18 $110,015 - $146,587
2,150 Added 20.48%
12,650 $683,000
Q4 2023

Jan 23, 2024

BUY
$38.62 - $72.18 $169,928 - $317,592
4,400 Added 72.13%
10,500 $657,000
Q3 2023

Oct 16, 2023

BUY
$45.39 - $59.0 $276,879 - $359,900
6,100 New
6,100 $277,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.74B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Leavell Investment Management, Inc. Portfolio

Follow Leavell Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Leavell Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Leavell Investment Management, Inc. with notifications on news.